Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ivermectin 1% Cream vs Soolantra in Healthy Adults
NCT06557603Phase 1Completed
- Sponsor
- Humanis
- Start
- Mar 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ivermectin in rosacea (2 arms), sponsored by Humanis. Primary endpoints: Maximum measured plasma concentration at 21 hours and Area under the plasma concentration versus time curve from time zero to the last quantifiable concentration at 21 hours. Started Mar 2024; status: completed.
02
Drugs
ivermectin
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT06557603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06557603.